Industry ETFs In The Spotlight: Winners And Losers Of The Month Revealed
The major U.S. stock indices, closely monitored through ETFs — the SPDR S&P 500 ETF Trust (NYSE:IWM) —…
Weight-Loss Drug Wegovy Adds Mass To Novo Nordisk’s stock, Pushing Valuation Past Denmark’s GDP
Shares of weight-loss drug manufacturers came to the party last week on the back of positive news flow…
Disinflation Talk Grows, Rate Hike Bets Plummet: Top 5 ETFs Rallying On CPI Miss
The disinflationary trend continued in July, even though the annual CPI inflation rate saw a slight increase from…
Rising Stars, Falling Trends: July’s Industry ETF Winners and Losers
As July comes to an end, it’s time to take a look at the best- and worst-performing industry…
Women’s Reproductive Rights: US Court Preserves Access To Abortion Pill For Now, But With Tighter Rules
A U.S. federal appeals court has temporarily blocked a decision by a Texas judge to halt the FDA's approval of a widely used abortion drug.
New York and California Prepare For Potential Mifepristone Ban In Texas With Stockpiling Of Alternative Abortion Medications
New York and California are stockpiling an alternative abortion medication in case a Texas judge's order suspending the FDA approval of the primary drug, mifepristone, goes into effect later this week.
Attorney Generals of Over 20 States Sound Alarm Over Suspension Of Abortion Med Approval: “Devastating Risks” Ahead
In a new court filing, the Democratic attorneys general for 23 U.S. states have reportedly warned that a federal judge's decision to suspend the FDA's approval of mifepristone "presents devastating risks to millions of people," including those in states where abortion remains legal.
FDA Withdraws Lone Premature Birth Drug Makena Over Lack of Proven Benefits
Today, the FDA announced the final decision to withdraw approval of Privately held-Covis Pharma’s Makena (hydroxyprogesterone caproate injection), a drug approved…
AbbVie, Thermo Fisher Scientific And A Must-Watch Biotech ETF: CNBC’s ‘Final Trades’
On CNBC’s "Halftime Report Final Trades," Bryn Talkington of Requisite Capital Management said she is sticking with AbbVie Inc. (NYSE: ABBV), which has a 7.3% free cash flow yiel
Hefty Listing Price Of New Drugs For Cancer, Rare Diseases Put Pressure On Annual Hike For Older Drugs
New branded medicines are coming to market with ever-higher price tags as soon as the first day. Amgen Inc's (NASDAQ: AMGN) lung cancer treatment, Lumakras, carried a hefty price tag of $17,900 per patient monthly when it launched in 2021.